Dr. Javier Cortés, Head of the International Breast Cancer Center in Barcelona, Spain, reviews key insights from the recent ASCO meeting, focusing on the PEARLY trial, A-BRAVE, and I-SPY 2.2 abstracts.
Dr. Erika P. Hamilton shares the findings that bring fantastic news for patients with HER2+ breast cancer, showing an impressive improvement in survival by approximately 10 months.
Explore the findings of the PALMARES-2 study with Dr. Claudio Vernieri, offering crucial real-world insights into the efficacy of CDK4/6 inhibitors. Learn how these insights aid clinicians and patients in making informed treatment decisions for specific clinical settings.
Dr. Dominici Chairs ASCO’s "Breast Cancer Local/Regional/Adjuvant" therapy session where 9 abstracts covered a number of different topics, three of which look at some interesting additions to standard therapy.
Dr. Shaheena Dawood shares her excitement about the wealth of information related to patients with breast cancer and how this data will impact clinical practice. In particular, she highlights three crucial pieces of information from ASCO and reviews data from the DESTINY-Breast06 Update, post MONARCH study and updated analysis from the innovaTV207 trial.
Dr. Maryellen Giger discusses the exciting developments in artificial intelligence (AI) applied to breast cancer imaging. From risk assessment to early detection, diagnosis, prognosis, and treatment response, AI is making significant strides
Join Dr. Stephanie Wong at ASCO as she presents data on PARP inhibitor eligibility in women with newly diagnosed invasive breast cancer. This research is part of the GREAT AGATA Study, a universal genetic testing initiative aimed at improving patient outcomes.
Dr. Judy-Anne Williams Chapman, PhD, emphasizes her four decades of work on the critical topic of estrogen and progesterone receptors. She proposes an adjunctive statistical standardization of quantitated ER and PgR to enhance inter-laboratory comparability of biomarker results and improve the therapeutic management of breast cancer.
Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.
Join Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.
Join Dr. Matthew P. Goetz as he discusses the open-label, randomized, multicenter phase 3 ELAINE 3 study. This research investigates the efficacy and safety of lasofoxifene combined with abemaciclib for treating ER+/HER2- locally advanced or metastatic breast cancer with an ESR1 mutation. Discover the potential impact of these findings on patient care and treatment options.
Join Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.
Join Dr. Mark Basik as he presents the results of the TRICIA study, conducted across cancer centers and hospitals in Quebec and Ontario. Learn about the significant findings and the plans to initiate a clinical trial in the coming years, with the goal of advancing treatment options for this challenging type of cancer.
Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.
Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.
Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.
Dr. Asselah and Dr. Park discuss the impact of microenvironment interactions on tumor growth, treatment resistance, and potential therapeutic strategies with a focus on bridging basic to clinical research.
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen.
Dr. Javier Cortés, Head of the International Breast Cancer Center in Barcelona, Spain, reviews key insights from the recent ASCO meeting, focusing on the PEARLY trial, A-BRAVE, and I-SPY 2.2 abstracts.
Dr. Erika P. Hamilton shares the findings that bring fantastic news for patients with HER2+ breast cancer, showing an impressive improvement in survival by approximately 10 months.
Explore the findings of the PALMARES-2 study with Dr. Claudio Vernieri, offering crucial real-world insights into the efficacy of CDK4/6 inhibitors. Learn how these insights aid clinicians and patients in making informed treatment decisions for specific clinical settings.
Dr. Dominici Chairs ASCO’s "Breast Cancer Local/Regional/Adjuvant" therapy session where 9 abstracts covered a number of different topics, three of which look at some interesting additions to standard therapy.
Dr. Shaheena Dawood shares her excitement about the wealth of information related to patients with breast cancer and how this data will impact clinical practice. In particular, she highlights three crucial pieces of information from ASCO and reviews data from the DESTINY-Breast06 Update, post MONARCH study and updated analysis from the innovaTV207 trial.
Dr. Maryellen Giger discusses the exciting developments in artificial intelligence (AI) applied to breast cancer imaging. From risk assessment to early detection, diagnosis, prognosis, and treatment response, AI is making significant strides
Join Dr. Stephanie Wong at ASCO as she presents data on PARP inhibitor eligibility in women with newly diagnosed invasive breast cancer. This research is part of the GREAT AGATA Study, a universal genetic testing initiative aimed at improving patient outcomes.
Dr. Judy-Anne Williams Chapman, PhD, emphasizes her four decades of work on the critical topic of estrogen and progesterone receptors. She proposes an adjunctive statistical standardization of quantitated ER and PgR to enhance inter-laboratory comparability of biomarker results and improve the therapeutic management of breast cancer.
Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.
Join Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.
Join Dr. Matthew P. Goetz as he discusses the open-label, randomized, multicenter phase 3 ELAINE 3 study. This research investigates the efficacy and safety of lasofoxifene combined with abemaciclib for treating ER+/HER2- locally advanced or metastatic breast cancer with an ESR1 mutation. Discover the potential impact of these findings on patient care and treatment options.
Join Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.
Join Dr. Nagi S. El Saghir as he discusses new studies presented at ASCO 2024. He highlights recent studies on the sequencing of CDK4/6 inhibitors and endocrine therapy in patients with advanced breast cancer.
Join Dr. Mark Basik as he presents the results of the TRICIA study, conducted across cancer centers and hospitals in Quebec and Ontario. Learn about the significant findings and the plans to initiate a clinical trial in the coming years, with the goal of advancing treatment options for this challenging type of cancer.
Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.
Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.
Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
